Cargando…

A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report

BACKGROUND: Germline BRCA2 mutation is associated with an aggressive prostate cancer phenotype and indicates higher risk for hereditary cancer. Recently, numerous studies have attempted to identify the genomic landscape of prostate cancer to better understand the genomic drivers of this disease and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lijuan, Bai, Zunguang, Zhu, Shoulun, Zhao, Tingting, Yang, Yining, Li, Zhiyong, Chen, Dong, Wu, Zhiming, Wang, Yanjun, Zhou, Fangjian, Li, Yonghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381549/ https://www.ncbi.nlm.nih.gov/pubmed/34425813 http://dx.doi.org/10.1186/s12894-021-00879-4

Ejemplares similares

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study
por: wang, Ning, et al.
Publicado: (2021)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Prevalence and risk factors of incidental prostate cancer in certain surgeries for benign prostatic hyperplasia: A systematic review and meta-analysis
por: Guo, Zhenlang, et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
por: Pandya, Deep, et al.
Publicado: (2021)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study
por: Chen, Xi, et al.
Publicado: (2023)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

Prevalence and risk factors for incidental prostate cancer in patients after transurethral resection of the prostate with negative results on prostate biopsy: A retrospective study
por: Guo, Zhenlang, et al.
Publicado: (2022)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
por: Penson, Richard T., et al.
Publicado: (2020)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
por: Taylor, Renea A., et al.
Publicado: (2017)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
por: Yang, Zhenyu, et al.
Publicado: (2021)

Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
por: Valsecchi, Anna Amela, et al.
Publicado: (2023)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer
por: Agalliu, I, et al.
Publicado: (2007)

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
por: Dias, Alexander, et al.
Publicado: (2023)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
por: Turner, Nicholas C, et al.
Publicado: (2012)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Melanoma predisposition—A limited role for germline BRCA1 and BRCA2 variants
por: Adams, David J., et al.
Publicado: (2019)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Germline mutations in 5’ to c.7914 of BRCA2 significantly increase risk of prostate cancer
por: Ruan, Xiao-Hao, et al.
Publicado: (2022)

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation
por: Mitchell, Gillian, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ug5j00mmqilbkde2s84nmvqvb7